Tenecteplase interactions
Full monograph for TenecteplaseCheck it against another medicine
Medicines
94 documented
Mechanism
| Medicine | Severity | Mechanism | Effect | Sources |
|---|---|---|---|---|
| Acalabrutinib | Major | Synergy | Coadministration of acalabrutinib and drugs that interfere with platelet function or coagulation may potentiate the risk of bleeding complications. | 3 sources — open the full entry |
| Allium cepa + Heparin + Allantoin | Major | Synergy | Although this combination is used therapeutically and recommended for certain indications (e.g., acute myocardial infarction, pulmonary embolism), fibrinolytic… | 12 sources — open the full entry |
| Apixaban | Major | Synergy | Concomitant use of apixaban with other agents that alter hemostasis such as aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), platelet aggregation… | 39 sources — open the full entry |
| Betrixaban | Major | Synergy | Concomitant use of betrixaban with other agents that alter hemostasis such as aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), platelet aggregation… | 39 sources — open the full entry |
| Bivalirudin | Major | Synergy | The concomitant administration of thrombin inhibitors and thrombolytic agents may increase the risk of bleeding complications. Intracranial bleeding has been… | 1 sources — open the full entry |
| Cabozantinib | Major | Synergy | Coadministration of cabozantinib and drugs that interfere with platelet function or coagulation may potentiate the risk of bleeding complications. Treatment… | 39 sources — open the full entry |
| Dabigatran Etexilate Mesylate | Major | Synergy | Drugs that can affect hemostasis such as glycoprotein IIb/IIIa inhibitors, thienopyridine antiplatelet agents, unfractionated and low molecular weight… | 3 sources — open the full entry |
| Dalteparin Sodium | Major | Synergy | Drugs that can affect hemostasis such as dextran, platelet inhibitors, thrombin inhibitors, thrombolytic agents, or other anticoagulants may potentiate the… | 7 sources — open the full entry |
| Dasatinib | Major | Synergy | Coadministration of dasatinib and drugs that interfere with platelet function or coagulation may potentiate the risk of bleeding complications. Treatment with… | 5 sources — open the full entry |
| Deferasirox | Major | Synergy | Coadministration with drugs that have known ulcerogenic or hemorrhagic potential may increase the risk of gastrointestinal bleeding associated with the use of… | 3 sources — open the full entry |
| Enoxaparin Sodium | Major | Synergy | Drugs that can affect hemostasis such as dextran, platelet inhibitors, thrombin inhibitors, thrombolytic agents, or other anticoagulants may potentiate the… | 7 sources — open the full entry |
| Eptifibatide | Major | Synergy | The intended and unintended effects of glycoprotein IIb/IIIa inhibitors and thrombolytic agents are additive, such that there is an increased frequency of… | 4 sources — open the full entry |
| Fondaparinux Sodium | Major | Synergy | Drugs that can affect hemostasis such as dextran, platelet inhibitors, thrombin inhibitors, thrombolytic agents, or other anticoagulants may potentiate the… | 7 sources — open the full entry |
| Heparin Sodium | Major | Synergy | Although this combination is used therapeutically and recommended for certain indications (e.g., acute myocardial infarction, pulmonary embolism), fibrinolytic… | 12 sources — open the full entry |
| Ibrutinib | Major | Synergy | Coadministration of ibrutinib and drugs that interfere with platelet function or coagulation may potentiate the risk of bleeding complications. | 6 sources — open the full entry |
| Ponatinib Hydrochloride | Major | Synergy | Coadministration of ponatinib and drugs that interfere with platelet function or coagulation may potentiate the risk of bleeding complications. Treatment with… | 3 sources — open the full entry |
| Prasugrel Hydrochloride | Major | Synergy | Concomitant use of prasugrel with other agents that affect hemostasis such as anticoagulants, platelet inhibitors, thrombin inhibitors, thrombolytic agents… | 2 sources — open the full entry |
| Ramucirumab | Major | Synergy | Coadministration of ramucirumab and drugs that interfere with platelet function or coagulation may potentiate the risk of bleeding complications. Ramucirumab… | 2 sources — open the full entry |
| Regorafenib Monohydrate | Major | Synergy | Coadministration of regorafenib and drugs that interfere with platelet function or coagulation may potentiate the risk of bleeding complications. Treatment… | 5 sources — open the full entry |
| Rivaroxaban | Major | Synergy | Concomitant use of rivaroxaban with other agents that alter hemostasis such as aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), platelet aggregation… | 1 sources — open the full entry |
| Tirofiban Hydrochloride | Major | Synergy | The intended and unintended effects of glycoprotein IIb/IIIa inhibitors and thrombolytic agents are additive, such that there is an increased frequency of… | 4 sources — open the full entry |
| Warfarin Sodium | Major | Synergy | Although warfarin is commonly administered for the prevention of embolism in certain patients following thrombolytic therapy (e.g., myocardial infarction)… | 47 sources — open the full entry |
| Aminocaproic acid | Moderate | Antagonism | Coadministration of an antifibrinolytic agent (e.g., aminocaproic acid, tranexamic acid, aprotinin) in combination with a tissue plasminogen activator (t-PA)… | 4 sources — open the full entry |
| Aspirin | Moderate | Synergy | Drugs that inhibit platelet function may increase the risk of bleeding when administered prior to, during, or after thrombolytic therapy. | 8 sources — open the full entry |
| Aspirin + Dipyridamole | Moderate | Synergy | Drugs that inhibit platelet function may increase the risk of bleeding when administered prior to, during, or after thrombolytic therapy.2 documented mechanisms | 8 sources — open the full entry |
| Benzoic Acid + Salicylic Acid | Moderate | Synergy | Drugs that inhibit platelet function may increase the risk of bleeding when administered prior to, during, or after thrombolytic therapy. | 8 sources — open the full entry |
| Betamethasone Dipropionate + Salicylic Acid | Moderate | Synergy | Drugs that inhibit platelet function may increase the risk of bleeding when administered prior to, during, or after thrombolytic therapy. | 8 sources — open the full entry |
| Bromfenac Sodium | Moderate | Synergy | Systemically and topically administered nonsteroidal anti-inflammatory drugs (NSAIDs) may potentiate the risk of bleeding in patients treated with… | 3 sources — open the full entry |
| Captopril | Moderate | Synergy | Coadministration of a tissue plasminogen activator with an angiotensin enzyme converting (ACE) inhibitor may increase the risk of angioedema and anaphylactoid… | 6 sources — open the full entry |
| Cetalkonium Chloride + Choline Salicylate | Moderate | Synergy | Drugs that inhibit platelet function may increase the risk of bleeding when administered prior to, during, or after thrombolytic therapy. | 8 sources — open the full entry |
| Cilostazol | Moderate | Synergy | Drugs that inhibit platelet function may increase the risk of bleeding when administered prior to, during, or after thrombolytic therapy. | 8 sources — open the full entry |
| Citalopram Hydrobromide | Moderate | Synergy | Serotonin reuptake inhibitors (SRIs) may potentiate the risk of bleeding in patients treated with ulcerogenic agents and agents that affect hemostasis such as… | 42 sources — open the full entry |
| Clobetasol Propionate + Salicylic Acid | Moderate | Synergy | Drugs that inhibit platelet function may increase the risk of bleeding when administered prior to, during, or after thrombolytic therapy. | 8 sources — open the full entry |
| Clomipramine Hydrochloride | Moderate | Synergy | Serotonin reuptake inhibitors (SRIs) may potentiate the risk of bleeding in patients treated with ulcerogenic agents and agents that affect hemostasis such as… | 42 sources — open the full entry |
| Clopidogrel + Aspirin | Moderate | Synergy | Drugs that inhibit platelet function may increase the risk of bleeding when administered prior to, during, or after thrombolytic therapy.2 documented mechanisms | 8 sources — open the full entry |
| Clopidogrel Bisulphate | Moderate | Synergy | Drugs that inhibit platelet function may increase the risk of bleeding when administered prior to, during, or after thrombolytic therapy. | 8 sources — open the full entry |
| Coal Tar + Precipitated Sulphur + Salicylic Acid | Moderate | Synergy | Drugs that inhibit platelet function may increase the risk of bleeding when administered prior to, during, or after thrombolytic therapy. | 8 sources — open the full entry |
| Desvenlafaxine Succinate | Moderate | Synergy | Serotonin reuptake inhibitors (SRIs) may potentiate the risk of bleeding in patients treated with ulcerogenic agents and agents that affect hemostasis such as… | 42 sources — open the full entry |
| Dexibuprofen | Moderate | Synergy | Systemically and topically administered nonsteroidal anti-inflammatory drugs (NSAIDs) may potentiate the risk of bleeding in patients treated with… | 3 sources — open the full entry |
| Dexketoprofen | Moderate | Synergy | Systemically and topically administered nonsteroidal anti-inflammatory drugs (NSAIDs) may potentiate the risk of bleeding in patients treated with… | 3 sources — open the full entry |
| Diclofenac Diethylamine + Mephenesin + Menthol + Methyl Salicylate + Turpentine Oil | Moderate | Synergy | Systemically and topically administered nonsteroidal anti-inflammatory drugs (NSAIDs) may potentiate the risk of bleeding in patients treated with… | 3 sources — open the full entry |
| Diclofenac Potassium | Moderate | Synergy | Systemically and topically administered nonsteroidal anti-inflammatory drugs (NSAIDs) may potentiate the risk of bleeding in patients treated with… | 3 sources — open the full entry |
| Diclofenac Sodium | Moderate | Synergy | Systemically and topically administered nonsteroidal anti-inflammatory drugs (NSAIDs) may potentiate the risk of bleeding in patients treated with… | 3 sources — open the full entry |
| Diclofenac Sodium (Ophthalmic) | Moderate | Synergy | Systemically and topically administered nonsteroidal anti-inflammatory drugs (NSAIDs) may potentiate the risk of bleeding in patients treated with… | 3 sources — open the full entry |
| Diclofenac Sodium + Lidocaine Hydrochloride | Moderate | Synergy | Systemically and topically administered nonsteroidal anti-inflammatory drugs (NSAIDs) may potentiate the risk of bleeding in patients treated with… | 3 sources — open the full entry |
| Diclofenac Sodium + Methyl Salicylate + Linseed Oil + Menthol | Moderate | Synergy | Systemically and topically administered nonsteroidal anti-inflammatory drugs (NSAIDs) may potentiate the risk of bleeding in patients treated with… | 3 sources — open the full entry |
| Diclofenac Sodium + Misoprostol | Moderate | Synergy | Systemically and topically administered nonsteroidal anti-inflammatory drugs (NSAIDs) may potentiate the risk of bleeding in patients treated with… | 3 sources — open the full entry |
| Dipyridamole | Moderate | Synergy | Drugs that inhibit platelet function may increase the risk of bleeding when administered prior to, during, or after thrombolytic therapy. | 8 sources — open the full entry |
| Dithranol + Boric Acid + Salicylic Acid | Moderate | Synergy | Drugs that inhibit platelet function may increase the risk of bleeding when administered prior to, during, or after thrombolytic therapy. | 8 sources — open the full entry |
| Duloxetine Hydrochloride | Moderate | Synergy | Serotonin reuptake inhibitors (SRIs) may potentiate the risk of bleeding in patients treated with ulcerogenic agents and agents that affect hemostasis such as… | 42 sources — open the full entry |
Conditions
Conditions in which Tenecteplase needs care, as documented in this source.
Hemorrhage
MajorThe most common complication encountered during tenecteplase therapy is bleeding. Tenecteplase therapy in patients with acute myocardial infarction is contraindicated in patients with active internal bleeding, history of cerebrovascular accident, intracranial or intraspinal surgery or trauma within 2 months, intracranial neoplasms, arteriovenous malformations or aneurysm, bleeding diathesis or severe uncontrolled hypertension, due to an increased risk of bleeding. Each patient being considered for therapy should be carefully evaluated and anticipated benefits weighed against potential risks associated with therapy.
1 source
- "Product Information. TNKase (tenecteplase)." Genentech (2001):
Thromboembolism
ModerateThe use of tenecteplase can increase the risk of thromboembolic events in patients with high likelihood of left heart thrombus, such as patients with mitral stenosis or atrial fibrillation. Caution and monitoring is advised.
1 source
- "Product Information. TNKase (tenecteplase)." Genentech (2001):